Published Date: 08 Mar 2023
The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).
Read Full News1.
Survival is extended by a new treatment option for metastatic colorectal cancer.
2.
Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.
3.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
4.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
5.
The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.
1.
Cutting-Edge Cancer Care: The Precision Revolution in Surgical Oncology
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
4.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
5.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation